Rouen-based medtech startup Robocath designs, develops, and commercializes cardiovascular robotic systems for the treatment of vascular diseases such as heart attack and stroke. The startup has raised €5 million to support the rollout of its robotic platform in strategic European target markets. The company has also hired Lucien Goffart as CEO.
With twenty years of experience in cardiology, Lucien Goffart has held a number of key positions in leading companies in the sector. He also has a strong track record of supporting international marketing of new products. His background notably includes a position as a business manager for France at Boston Scientific, and his recent appointment as an executive board member at Electroducer, a French manufacturer of vascular devices.
“I’m delighted to welcome Lucien Goffart to the company at such a key moment for us with the commercial launch of our first robotic platform,” said Philippe Bencteux, founder & president of Robocath. “His experience in the industry is undeniable. This appointment has been made at a particularly auspicious time, with our only direct competitor, Corindus Vascular Robotics, having been bought out by Siemens for €1 billion.”
“It’s an honor for me to begin work today as CEO of Robocath,” said Lucien Goffart, CEO of Robocath. “I’m impressed by the progress the company has made since it was founded and I’m excited to be working with such a young and dynamic team. R-One™ is a unique product that offers several advantages to physicians and, by extension, to patients. It has significant potential on the market, and I’m looking forward to starting clinical studies and writing a brand new page in the history of interventional cardiology.”
The €5 million capital injection was provided by existing shareholders GO CAPITAL, NCI, Normandie Participations, M Capital, and Supernova Invest, as well as new funds Caisse d’Epargne Normandie Innovation, Crédit Agricole innove en Normandie and Unexo, a subsidiary of the Crédit Agricole group. The company previously raised €6.4 million in 2017. This new injection will allow Robocath to lay the groundwork for rolling out the R-One™ robotic platform in a number of target European countries.